n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)

Biogen Earnings Rise, Matching Estimates

The biotech company said net income in the fourth quarter totaled $207.7 million, or 70 cents a share, compared with net income of $201 million, or 67 cents a share, a year earlier.

Biotech Stock Roundup: Amylin Ascends

Amylin shares are rising on news that billionaire investor Carl Icahn is building his position in the company.

Allergan Reports Saggy Profit, Jobs Cuts

Botox maker Allergan says fourth-quarter profit fell to $150.6 million, or 50 cents per share, from $160.3 million, or 52 cents per share, in the fourth quarter of 2008.

Biotech Stock Mailbag: My Say on Sequenom

Biotech Stock Mailbag: My Say on Sequenom

Travis T. takes umbrage with an article on Sequenom's latest Down syndrome data.

Pfizer Gambles on Building an Alzheimer's Empire

Pfizer Gambles on Building an Alzheimer's Empire

A bid for Wyeth could help Pfizer dominate the Alzheimer's drug market, but doing so carries big risks and challenges.

Top Takes From RealMoney

Top Takes From RealMoney

Here's what some of our market pros are saying and playing.

Wyeth Deal's Big, but Pfizer Still Needs a Blockbuster

Wyeth Deal's Big, but Pfizer Still Needs a Blockbuster

If Pfizer's looking for the next Lipitor, it probably hasn't found it with the acquisition of Wyeth.

So Much for a Pfizer Biotech Play

So Much for a Pfizer Biotech Play

Looks like Pfizer's ordering the usual, and if talks to buy fellow drug giant Wyeth pan out, biotech stocks may get burned.

Top Takes From RealMoney

Top Takes From RealMoney

Here's what some of our market pros are saying and playing.

Biogen Drops on News of Potential MS Pill Rival

Biogen Drops on News of Potential MS Pill Rival

Biogen Idec shares were sliding on concerns that a competitor's oral pill for multiple sclerosis may pinch the company's profits.

Highlights From the J.P. Morgan Health Confab

Adam Feuerstein gives the lowdown on this year's conference in San Francisco.

Elan Would Consider Selling, but Who'd Buy It?

Biotech expert Adam Feuerstein explains a sale isn't likely here, regardless of what the company's management says.

Elan Mulling Possible Sale, Merger

Dublin's Elan has hired Citigroup Global Markets to review alternatives, including a minority investment, an alliance, or a merger or sale of the company.

Biotech Confab Preview: Stocks to Watch

The J.P. Morgan Healthcare Conference kicks off Monday in San Francisco amid troubled times for the biotech sector. Here are some of the top stories to watch for.

'Fast Money' Recap: The Retail Blues

The trading panel discussed the big drop in Wal-Mart stock.

Amazon Options Bet Against Further Gains

Elan and Materials Select SPDR are also seeing options activity.

Biotech Scorecard: My Best and Worst Calls

Biotech expert Adam Feuerstein grades his hits and misses for 2008.

Biotech Mailbag 2008 Review

Here's a look back at the hits, misses and notable moments from 2008.

Biotech Mailbag: Bad CEOs Offer Lessons

Senior Columnist Adam Feuerstein's selection of Kelly Martin as the worst biotech CEO for 2008 highlights the need for investors to scrutinize management teams before plunging into an investment.

Myriad Genetics' Meldrum Is Best In Biotech

Peter Meldrum Wins Swanson Trophy for pulling off one of the smartest drug licensing deals of all time.

Major Elan Shareholder Targets CEO

Major Elan Shareholder Targets CEO

Elan CEO Kelly Martin, Senior Columnist Adam Feuerstein's pick for worst biotech CEO of 2008, is in the crosshairs of a major investor.

Novartis MS Drug Reduces Relapses

A study showed the company's experimental daily pill for multiple sclerosis was more effective than a currently approved injectable drug from Biogen Idec.

Elan's Martin Named Worst Biotech CEO of '08

Kelly Martin is taking home the Nance Trophy for oustanding achievement in loss of shareholder value, overstated optimism and abject incompetence under pressure.

Health Winners & Losers: BioMimetic

Conceptus is up 43%.

Biogen Falls on Infection Report (Update)

The biotech has revealed in a regulatory filing a third case of PML, an often deadly infection, in an MS patient taking Tysabri.

Biogen Confirms Third Brain Infection

Biogen Confirms Third Brain Infection

The biotech reveals in a regulatory filing a third case of PML, an often deadly infection, in an MS patient taking Tysabri.

Health Winners & Losers: Amylin

Also, shares of GlaxoSmithKline fall.

Health Winners & Losers: Amgen, Mentor

Amgen rises on an upheld court ruling regarding two anemia drugs. Mentor shares fall on UBS rating.

Cramer's Take on Top-Searched Stocks

Freeport-McMoRan is among the most-searched stocks on TheStreet.com. Here's what Cramer's had to say about it lately.

'Mad Money Lightning Round': Wait for Wachovia

'Mad Money Lightning Round': Wait for Wachovia

Cramer likes the top executive at this bank.